![Connie Lebakken](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
Connie Lebakken is associated with Stem Pharm, Inc. as the founder and currently holds the title of President since 2015.
Actieve functies van Connie Lebakken
Bedrijven | Functie | Begin |
---|---|---|
Stem Pharm, Inc.
![]() Stem Pharm, Inc. Medical DistributorsDistribution Services Stem Pharm, Inc. is a neurological drug discovery platform company that uses a human-first approach to develop the next-generation of neurologic drugs. The company is based in Madison, WI, a hub for innovative stem cell and biosciences research. The company's proprietary drug discovery platform is based on human 3D neuro-immune organoids that feature microglia and model neuroinflammation, which play a critical role in many neurological diseases. Stem Pharm applies this platform to discover and validate disease targets and therapeutics for its internal programs in epilepsy, neurodegeneration, and brain cancer as well as for its biopharma partners' therapeutic programs. The company was founded in 2015 by William L. Murphy, Connie Lebakken, and the CEO is Steven R. Visuri. | Oprichter | 01-01-2015 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Stem Pharm, Inc.
![]() Stem Pharm, Inc. Medical DistributorsDistribution Services Stem Pharm, Inc. is a neurological drug discovery platform company that uses a human-first approach to develop the next-generation of neurologic drugs. The company is based in Madison, WI, a hub for innovative stem cell and biosciences research. The company's proprietary drug discovery platform is based on human 3D neuro-immune organoids that feature microglia and model neuroinflammation, which play a critical role in many neurological diseases. Stem Pharm applies this platform to discover and validate disease targets and therapeutics for its internal programs in epilepsy, neurodegeneration, and brain cancer as well as for its biopharma partners' therapeutic programs. The company was founded in 2015 by William L. Murphy, Connie Lebakken, and the CEO is Steven R. Visuri. | Distribution Services |